83rd Annual Meeting of the American Association for Cancer Research

May 20-23, 1992
San Diego, CA

• Program Committee Chairperson
  WEBSTER K. CAVENEE, San Diego, CA

• Topics and Chairpersons of Major Scientific Events

  "Chemoprevention of Cancer"
  MICHAEL B. SPORN / Bethesda, MD

  "Innovative Tumor Immunology"
  TAK W. MAK / Toronto, Ontario, Canada

  "Molecular Approaches to Diagnosis and Patient Evaluation"
  MARK A. ISRAEL / San Francisco, CA

  "p53 Tumor Suppressor Gene"
  CURTIS C. HARRIS / Bethesda, MD

  "Gene Expression and Chromatin Structure"
  WILLIAM T. GARRARD / Dallas, TX

  "Genomic Instability and Cancer"
  THEA D. TLSTY / Chapel Hill, NC

  "Hereditary Predisposition to Cancer"
  FREDERICK P. LI / Boston, MA

  "HIV-Associated Maligancies"
  FLOSSIE WONG-STAAI / La Jolla, CA

  "Cytokines/Receptors"
  JOHN MENDELSOHN / New York, NY

  "The Role of Cell Adhesion in Invasion and Metastasis"
  ERKKI RUOSLAHTI / La Jolla, CA

  "Cell Cycle Control"
  DAVID BEACH / Cold Spring Harbor, NY

  "Molecular Carcinogenesis"
  SARASWATI SUKUMAR / La Jolla, CA

  "Drug Design/Discovery"
  DANIEL D. VON HOFF / San Antonio, TX

  "Breast Cancer"
  DENNIS J. SLamon / Los Angeles, CA

  "Receptor Signalling/Transduction"
  JOSEPH SCHLESSINGER / New York, NY

  "Molecular Genetics of Cancer"
  ERIC J. STANBRIDGE / Irvine, CA

  "Programmed Cell Death (Apoptosis) in the Etiology and Therapy of Cancer"
  JOHN T. ISAACS / Baltimore, MD

  "Novel Chemotherapy"
  JUDAH M. FOLKMAN / Boston, MA

• Special Lectures
  Presidential Address: HAROLD L. MOSES, Nashville, TN
  Five Additional Award Lectures

• Sessions of Proffered Papers
  Minisymposia, poster discussion sessions, and regular poster sessions will be organized from submitted papers in all areas of cancer research.

• Information, Registration Forms, and Membership Application Forms available immediately upon request from

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

Telephone: 215-440-9300 • FAX: 215-440-9313

• Information also available on AACR Special Conferences in Cancer Research, the Association's series of smaller meetings focused on rapidly developing areas of molecular biology and cancer research.
Featured on the cover of this issue of Cancer Research are the 1991 awardees of the Medal of Honor of the American Cancer Society. Dr. Gianni Bonadonna, bottom left, was recognized for major contributions to chemotherapy. He was the first to describe the wide range of therapeutic efficacy of Adriamycin (doxorubicin) as well as its clinical toxicity (Cancer Res., 30: 2572–2582, 1970) and other landmark developments of combination therapy. In a series of sequential, carefully controlled studies, he demonstrated the effectiveness of ABVD [Adriamycin, bleomycin, vinblastine, and dacarbazine] in MOPP [mechloretamine, Oncovin (vincristine), procarbazine, and prednisone]-resistant Hodgkin’s disease and conducted the first trials of the use of adjuvant chemotherapy in operable breast cancer with CMF [cyclophosphamide, methotrexate, and 5-fluorouracil] [N. Engl. J. Med., 294: 405–410, 1976]. The efficacy of this treatment, now being applied throughout the world, has been recently confirmed by the International Overview on Early Breast Cancer. More recently, he has demonstrated that primary (neoadjuvant) chemotherapy can effectively increase the indication for conservative surgery in women who were otherwise candidates for mastectomy (J. Clin. Oncol., 7: 1380–1397, 1989; J. Natl. Cancer Inst., 82: 1539–1545, 1990).

Dr. Bonadonna graduated from the University of Milan School of Medicine in 1959, and after postdoctoral experience at the Memorial Sloan-Kettering Cancer Center in New York, he returned in 1964 to the National Tumor Institute in Milan, where he is now Director of the Division of Medical Oncology. He is prominent worldwide in medical oncology activities and has held many visiting professorships; is on numerous editorial boards, including that of Cancer Research; and has received numerous awards, including the Rosenthal Award of the AACR.

Dr. Louis Sullivan, Secretary of Health and Human Services, right, was honored for his efforts in protection against lung and other cancers through smoking cessation. He was recently featured on the cover of the July 1, 1989 issue of Cancer Research.

Dr. T. C. Hsu, top left, is acclaimed for many advances in the genetics of cancer. During his postdoctoral training with C. M. Pomerat at the Galveston campus of the University of Texas, he discovered that when human cells are immersed in a hypotonic solution prior to fixation, their metaphase chromosomes are spread apart and are clearly delineated. This major discovery set the stage for human and mammalian genetics, including gene mapping, genome analysis, and cancer etiology. Much of his subsequent career was devoted to details of cell organelles, and this led to a second major advance, a procedure for revealing heterochromatin. During the last decade, he has combined cytogenticics, mutagenesis, and cancer epidemiology to propose that a basis of cancer susceptibility is due to differences in mutagen sensitivity resulting from differences in DNA repair capability.

Dr. Hsu received his Ph.D. from the University of Texas Austin in 1951. In 1955, after postdoctoral research in Galveston and Austin, he joined the University of Texas M. D. Anderson Hospital and Tumor Institute in Houston, where he is now Professor Emeritus in genetics. He is very active in genetics and cell culture programs; holds numerous international memberships and positions on editorial boards, including that of Cancer Research; and has received many professional awards and officerships throughout the world.

We are grateful to the authors for information provided.

Sidney Weinhouse